Clinical significance of minimal residual disease in leukemia.

  • Authors:
    • S Faderl
    • H M Kantarjian
    • M Talpaz
    • Z Estrov
  • View Affiliations

  • Published online on: December 1, 2000     https://doi.org/10.3892/ijo.17.6.1277
  • Pages: 1277-1364
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Considerable progress has been made in the treatment of acute and chronic leukemias. Remission rates are generally high and cure rates of up to 80% can be achieved in children with acute lymphoblastic leukemia (ALL). However, in many patients the disease will ultimately recur. In most if not all of these patients, relapse is thought to result from subclinical levels of residual leukemia, termed minimal residual disease (MRD). Therefore, the study of MRD holds a significant potential to understand the biology of relapse and remission and to design new therapies to improve the cure rate of patients. A major goal of these studies is to be able and identify patients at a defined risk of relapse which can lead to risk-adapted therapy approaches. Laboratory assays such as polymerase chain reaction (PCR) and multicolor flow cytometry are sensitive enough to detect one leukemic cell in up to 104-105 normal cells and have become ideal tools to monitor MRD. Especially PCR has been used extensively. Although a wealth of data has been generated, some questions remain as to the impact of monitoring MRD on clinical outcome and are the object of this review.

Related Articles

Journal Cover

Dec 2000
Volume 17 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Faderl S, Kantarjian H, Talpaz M and Estrov Z: Clinical significance of minimal residual disease in leukemia.. Int J Oncol 17: 1277-1364, 2000.
APA
Faderl, S., Kantarjian, H., Talpaz, M., & Estrov, Z. (2000). Clinical significance of minimal residual disease in leukemia.. International Journal of Oncology, 17, 1277-1364. https://doi.org/10.3892/ijo.17.6.1277
MLA
Faderl, S., Kantarjian, H., Talpaz, M., Estrov, Z."Clinical significance of minimal residual disease in leukemia.". International Journal of Oncology 17.6 (2000): 1277-1364.
Chicago
Faderl, S., Kantarjian, H., Talpaz, M., Estrov, Z."Clinical significance of minimal residual disease in leukemia.". International Journal of Oncology 17, no. 6 (2000): 1277-1364. https://doi.org/10.3892/ijo.17.6.1277